101 related articles for article (PubMed ID: 19554535)
1. [Multiple peritrochanteric and pubic calcifications in a young woman on hemodialysis with severe renal osteodystrophy successfully treated with sevelamer+cinacalcet+paracalcitol combination therapy].
Bellotti G; Presta P; Panzino T; Capria M; Caglioti A; Riccio M; Bova F; Fuiano L; Fuiano G
G Ital Nefrol; 2009; 26(3):372-6. PubMed ID: 19554535
[TBL] [Abstract][Full Text] [Related]
2. Effects of sevelamer hydrochloride and calcium carbonate on renal osteodystrophy in hemodialysis patients.
Ferreira A; Frazão JM; Monier-Faugere MC; Gil C; Galvao J; Oliveira C; Baldaia J; Rodrigues I; Santos C; Ribeiro S; Hoenger RM; Duggal A; Malluche HH;
J Am Soc Nephrol; 2008 Feb; 19(2):405-12. PubMed ID: 18199805
[TBL] [Abstract][Full Text] [Related]
3. Reversal of the adynamic bone disorder and decreased vascular calcification in chronic kidney disease by sevelamer carbonate therapy.
Mathew S; Lund RJ; Strebeck F; Tustison KS; Geurs T; Hruska KA
J Am Soc Nephrol; 2007 Jan; 18(1):122-30. PubMed ID: 17182886
[TBL] [Abstract][Full Text] [Related]
4. [New aspects in the management of renal osteodystrophy].
Matuszkiewicz-Rowińska J
Pol Arch Med Wewn; 2004 Oct; 112 Spec No():89-97. PubMed ID: 15669206
[TBL] [Abstract][Full Text] [Related]
5. Update on the treatment of chronic kidney disease-mineral and bone disorder.
Bover J; Farré N; Andrés E; Canal C; Olaya MT; Alonso M; Quílez B; Ballarín J
J Ren Care; 2009 Mar; 35 Suppl 1():19-27. PubMed ID: 19222727
[TBL] [Abstract][Full Text] [Related]
6. Combination therapy with sevelamer hydrochloride and calcium carbonate in Japanese patients with long-term hemodialysis: alternative approach for optimal mineral management.
Ogata H; Koiwa F; Shishido K; Kinugasa E
Ther Apher Dial; 2005 Feb; 9(1):11-5. PubMed ID: 15828900
[TBL] [Abstract][Full Text] [Related]
7. Calcific uremic arteriolopathy while on cinacalcet.
Gonzalez-Parra E; Martin-Cleary C; Martin J; Ortiz A
J Postgrad Med; 2011; 57(1):51-2. PubMed ID: 21206121
[No Abstract] [Full Text] [Related]
8. Role of cinacalcet in management of mineral bone disorder in chronic kidney disease (control of calcium, phosphorus and parathyroid hormone).
Tahara H
Ther Apher Dial; 2008 Oct; 12 Suppl 1():S27-33. PubMed ID: 19032524
[TBL] [Abstract][Full Text] [Related]
9. Cinacalcet hydrochloride therapy for secondary hyperparathyroidism in hemodialysis patients.
El-Shafey EM; Alsahow AE; Alsaran K; Sabry AA; Atia M
Ther Apher Dial; 2011 Dec; 15(6):547-55. PubMed ID: 22107691
[TBL] [Abstract][Full Text] [Related]
10. Effects of treatment of renal osteodystrophy on bone histology.
Malluche HH; Mawad H; Monier-Faugere MC
Clin J Am Soc Nephrol; 2008 Nov; 3 Suppl 3(Suppl 3):S157-63. PubMed ID: 18988701
[TBL] [Abstract][Full Text] [Related]
11. Impact of cinacalcet hydrochloride on bone histology in patients with secondary hyperparathyroidism.
Yajima A; Akizawa T; Tsukamoto Y; Kurihara S; Ito A;
Ther Apher Dial; 2008 Oct; 12 Suppl 1():S38-43. PubMed ID: 19032526
[TBL] [Abstract][Full Text] [Related]
12. Diffuse uremic tumoral calcinosis in a patient on long-term hemodialysis.
Akasbi N; Houssaini TS; Rabhi S; Lahlou M; Boukhrissa A; Tahiri L; El Maaroufi C; Berrady R; Harzy T; Bono W
J Clin Rheumatol; 2011 Aug; 17(5):272-4. PubMed ID: 21778901
[TBL] [Abstract][Full Text] [Related]
13. [Sevelamer hydrochloride and K/DOQI guidelines].
Yumita S
Clin Calcium; 2005 Sep; 15 Suppl 1():180-4. PubMed ID: 16279022
[No Abstract] [Full Text] [Related]
14. A comparison of sevelamer hydrochloride with calcium acetate on biomarkers of bone turnover in hemodialysis patients.
Liu YL; Lin HH; Yu CC; Kuo HL; Yang YF; Chou CY; Lin PW; Liu JH; Liao PY; Huang CC
Ren Fail; 2006; 28(8):701-7. PubMed ID: 17162430
[TBL] [Abstract][Full Text] [Related]
15. Sevelamer hydrochloride dose-dependent increase in prevalence of severe acidosis in hemodialysis patients: analysis of nationwide statistical survey in Japan.
Oka Y; Miyazaki M; Matsuda H; Takatsu S; Katsube R; Mori T; Takehara K; Umeda Y; Uno F
Ther Apher Dial; 2014 Feb; 18(1):37-43. PubMed ID: 24499082
[TBL] [Abstract][Full Text] [Related]
16. Sevelamer hydrochloride prevents ectopic calcification and renal osteodystrophy in chronic renal failure rats.
Katsumata K; Kusano K; Hirata M; Tsunemi K; Nagano N; Burke SK; Fukushima N
Kidney Int; 2003 Aug; 64(2):441-50. PubMed ID: 12846739
[TBL] [Abstract][Full Text] [Related]
17. Consequences of the implementation of K/DOQI Clinical Practice Guidelines for Bone Metabolism and Disease in Chronic Kidney Disease in a population of patients on chronic hemodialysis.
Arenas MD; Alvarez-Ude F; Torregrosa V; Gil MT; Carretón MA; Moledous A; Nuñez C; Devesa R; Albiach B
J Nephrol; 2007; 20(4):453-61. PubMed ID: 17879212
[TBL] [Abstract][Full Text] [Related]
18. [Clinical advances in vascular calcification].
Fernández Giráldez ED
Nefrologia; 2008; 28 Suppl 5():33-7. PubMed ID: 18847418
[TBL] [Abstract][Full Text] [Related]
19. Pharmacological control of secondary hyperparathyroidism in chronic hemodialysis patients: cinacalcet is coming to Japan.
Iseki K
Expert Opin Pharmacother; 2008 Mar; 9(4):601-10. PubMed ID: 18312161
[TBL] [Abstract][Full Text] [Related]
20. Calcium-containing phosphate binders in dialysis patients with cardiovascular calcifications: should we CARE-2 avoid them?
Floege J
Nephrol Dial Transplant; 2008 Oct; 23(10):3050-2. PubMed ID: 18625662
[No Abstract] [Full Text] [Related]
[Next] [New Search]
